![Zheng Bin Yao](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Zheng Bin Yao
Chief Executive Officer at
ARRIVENT BIOPHARMA, INC.
Net worth: 22 M $ as of 2026-06-29
Profile
Dr. Zheng Bin Yao is an Independent Director at Alumis, Inc., a Chairman & Chief Executive Officer at Arrivent BioPharma, Inc. and an Independent Non-Executive Director at VISEN Pharmaceuticals.
He is on the Board of Directors at Alumis, Inc., VISEN Pharmaceuticals, Immune-Onc Therapeutics, Inc. and NiKang Therapeutics, Inc. Dr. Yao was previously employed as a Chairman, President & Chief Executive Officer by Viela Bio, Inc., an Independent Director by NexImmune, Inc., a Senior Vice President & Head-Immuno-Oncology by MedImmune LLC, a Vice President & Head-Research by Tanox, Inc., a Head-Immuno-Oncology Franchise by AstraZeneca PLC, and a Head-Immunology & Infectious Diseases by Genentech, Inc. He received his graduate degree from Anhui Medical University and a doctorate degree from the University of Iowa.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-04-20 | 613,138 ( 1.32% ) | 21 M $ | 2026-06-29 | |
ALUMIS INC. 0.02% | 2026-06-29 | 27,082 ( 0.02% ) | 762 087 $ | 2026-06-29 |
Zheng Bin Yao active positions
| Companies | Position | Start |
|---|---|---|
| ALUMIS INC. | Director/Board Member | 2021-05-31 |
| ARRIVENT BIOPHARMA, INC. | Chief Executive Officer | 2021-05-31 |
| VISEN PHARMACEUTICALS | Director/Board Member | 2021-03-31 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Director/Board Member | 2019-03-31 |
NiKang Therapeutics, Inc.
 NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Director/Board Member | - |
Former positions of Zheng Bin Yao
| Companies | Position | End |
|---|---|---|
| NEXIMMUNE, INC. | Director/Board Member | 2024-08-26 |
| VIELA BIO, INC. | Chief Executive Officer | 2021-03-14 |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 2018-01-31 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Corporate Officer/Principal | 2007-10-18 |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Zheng Bin Yao
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
63
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody and pharmaceutical solutions used for the treatment of allergic diseases | Health Technology |
NexImmune, Inc.
 NexImmune, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company that develops T cell immunotherapies | Health Technology |
University of Iowa
 University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anhui Medical University
 Anhui Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc. BiotechnologyHealth Technology Develops small molecule oncology medicines to help patients | Health Technology |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
Arrivent BioPharma, Inc.
 Arrivent BioPharma, Inc. Pharmaceuticals: OtherHealth Technology Engages in development and commercialization of cancer medicines | Health Technology |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
- Stock Market
- Insiders
- Zheng Bin Yao
